Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Aktualnosci Neurologiczne is a renowned open-access journal dedicated to the field of neurology, published by Medical Communications. As a crucial platform for the dissemination of neurological research, it has been operational since 2005, fostering an inclusive environment for scientific discourse and innovation. With an ISSN of 1641-9227, the journal aims to bridge the gap between clinical practice and research, offering a diverse range of articles that cover the latest developments in neurological science. Although its coverage in Scopus was discontinued after 2017, the journal continues to maintain a robust archive of scholarly articles that contribute to understanding neurological disorders. Researchers, healthcare professionals, and students interested in the latest trends and studies in neurology will find Aktualnosci Neurologiczne an invaluable resource, providing insights that drive advancements in the field. The journal operates from its address in Warsaw, Poland, and invites contributions from the global research community to enrich its content and impact.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE is a pivotal journal in the fields of neurology, psychiatry, and related medical disciplines, published by GEORG THIEME VERLAG KG in Germany. With a history dating back to 1955, this journal has evolved to address the dynamic nature of neurological and psychiatric research, offering valuable insights and advancements in the field. Despite holding a Q4 category status in various medical domains according to the 2023 quartiles, the journal continues to foster academic discussion and engagement among researchers and clinicians alike. It serves as a vital platform for disseminating knowledge through original research articles, reviews, and clinical studies, making it an essential resource for professionals and students aiming to stay abreast of the latest developments in mental health and neurological science. Although the journal currently does not offer open access options, its contribution to the academic community is significant, helping to illuminate the intricate relationships between neurological disorders and psychiatric conditions.

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

LYMPHOLOGY is a distinguished journal dedicated to the study of lymphatic biology, hematology, and immunology, published by the esteemed LYMPHOLOGY organization since its inception in 1968. As a key resource within the scientific community, it holds a notable place in the academic landscape with a 2023 Scopus ranking of #47 in Hematology and #120 in Immunology and Allergy, reflecting its commitment to advancing knowledge through empirical research and critical reviews. Although it is not an Open Access journal, its relevance is underlined by a Q3 category in both hematology and immunology, providing a platform for groundbreaking research that addresses key challenges in these fields. Researchers and professionals will find invaluable insights and innovative methodologies within its pages, reinforcing its role as a vital contributor to advancing scientific understanding and clinical practice in lymphology and related disciplines.

The JOURNAL OF CHILD NEUROLOGY is a distinguished publication in the critical fields of neurology and pediatrics, published by SAGE PUBLICATIONS INC. With its ISSN 0883-0738 and E-ISSN 1708-8283, this journal has been a pivotal resource since its inception in 1986, serving the needs of researchers, clinicians, and students dedicated to advancing the understanding and treatment of neurological disorders in children. As evidenced by its impressive Q2 rankings in both Neurology (clinical) and Pediatrics, Perinatology, and Child Health, the journal has established a reputable position within the academic community, ranking in the 75th percentile for pediatrics and the 53rd percentile for clinical neurology. This periodical not only contributes to the body of knowledge in child neurology but also promotes interdisciplinary collaboration, engaging a global audience through innovative research articles and case studies. Although the journal is not open access, it remains committed to disseminating high-quality research aimed at improving pediatric health outcomes, making it an essential read for professionals and researchers dedicated to this crucial area of medicine.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.